Cargando…
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is broadly recommended in many nephrological guidelines to prevent chronic kidney disease (CKD) progression. This work aimed to analyze the robustness of randomized controlled trials (RCTs) investigating the renal and cardiovascular outco...
Autores principales: | Capuano, Ivana, Buonanno, Pasquale, Riccio, Eleonora, Bianco, Antonio, Pisani, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605379/ https://www.ncbi.nlm.nih.gov/pubmed/36294504 http://dx.doi.org/10.3390/jcm11206184 |
Ejemplares similares
-
Pain in Fabry Disease: Could Spinal Cord Stimulation be a Solution?
por: Buonanno, Pasquale, et al.
Publicado: (2023) -
Role of the Renin Angiotensin Aldosterone System in the Pathogenesis of Sepsis-Induced Acute Kidney Injury: A Systematic Review
por: Tibi, Sedra, et al.
Publicado: (2023) -
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study
por: Riccio, Eleonora, et al.
Publicado: (2022) -
Independent regulation of renin–angiotensin–aldosterone system in the kidney
por: Nishiyama, Akira, et al.
Publicado: (2018) -
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
por: Riccio, Eleonora, et al.
Publicado: (2021)